



ISSN : 2347 - 2243

Indo - American Journal of Life Sciences and Biotechnology



<https://iajlb.org>

Email : editor@iajlb.com or iajlb.editor@gmail.com



Thyroid Function Abnormalities in Women With Polycystic Ovary Syndrome

Ciara Kavanagh¹●, Natalie Ashford²●, Ondrej Prochazka³●

¹Scientist, Department of Biochemistry, Shannon Estuary Institute of Nursing and Health Sciences, Ennis, Ireland.

²Senior Scientist, Department of Plant Biochemistry, Cumberland Plateau Institute of Life Sciences, Cookeville, USA.

³Senior Research Fellow, Department of Biochemistry, Bohemian Forest Institute of Bioinformatics, Klatovy, Czech Republic.

Email: ¹c.kavanagh@seinhhs.ie, ²n.ashford@cpils.edu, ³o.prochazka@bfib.cz

ORCID: ¹0000-0001-1152-342X, ²0000-0001-1669-6063, ³0000-0001-1762-1071

Received: April 19, 2019 Accepted: August 3, 2019 Published: November 12, 2019

DOI: [10.62644/iajlb.2019.v16.i4.pp19-26](https://doi.org/10.62644/iajlb.2019.v16.i4.pp19-26)

ABSTRACT

Polycystic ovary syndrome (PCOS) is among the commonest endocrine conditions of women of reproductive age, and thyroid disease is among the commonest endocrine conditions of women in general. It is hardly surprising that the two are often found together, but whether they are linked by more than chance is less clear. This narrative review asks what the published literature says about thyroid function abnormalities in women with PCOS, how those abnormalities are defined and measured, and how much weight the evidence can bear. It draws on work on the diagnosis of PCOS, thyroid physiology and autoimmunity, insulin resistance and adiposity, and reproductive and pregnancy outcomes, and it reports no new data. Several studies describe more frequent subclinical hypothyroidism and thyroid autoimmunity in women with PCOS, but the reports differ in diagnostic criteria, reference ranges, body weight, iodine status and the populations sampled, and many are small, single-centre and cross-sectional. Two broad explanations are discussed: a shared autoimmune or hormonal background, and a metabolic route through insulin resistance and adiposity. Neither has been shown to be sufficient. The review concludes that thyroid testing in PCOS is reasonable, that a single raised thyrotropin result should be interpreted with care, and that larger, prospective studies using consistent criteria are needed.

Keywords: Polycystic ovary syndrome; Thyroid function; Subclinical hypothyroidism; Thyroid autoimmunity; Insulin resistance; Narrative review

Citation: Kavanagh, Ashford and Prochazka [2019]. Thyroid Function Abnormalities in Women With Polycystic Ovary Syndrome. *Indo-Am. J. Life Sci. Biotechnol.* 16(4):19-26. DOI: [10.62644/iajlb.2019.v16.i4.pp19-26](https://doi.org/10.62644/iajlb.2019.v16.i4.pp19-26)

Article Class: Narrative Review

1. Introduction

Polycystic ovary syndrome (PCOS) is one of the commonest endocrine conditions of women of reproductive age. It is diagnosed on a combination of irregular ovulation,

signs of androgen excess and, in some definitions, ovarian appearance on ultrasound (1, 2), and it carries metabolic and reproductive consequences well beyond the menstrual cycle (3, 4). Thyroid



disease is also common in women, particularly mild hypothyroidism and thyroid autoimmunity (5, 6), so some overlap is expected by chance alone.

The question is whether the overlap in PCOS exceeds chance, and if so, why. Several clinical series report raised thyrotropin and thyroid antibodies more often in women with PCOS than in comparison groups (7, 8, 9); others find little difference. Because thyroid hormone influences ovulation, body weight and pregnancy (10, 11), an unrecognised thyroid problem is not trivial.

This article reviews how thyroid status is defined and measured in women with PCOS, which autoimmune and metabolic routes might link the two conditions, and how far the reported associations can be trusted. No new patient data are presented and no local series is reported. The aim is a fair account of what is known and what is merely repeated.

2. Literature Review

2.1 Polycystic Ovary Syndrome: Definition and Variation

No single test diagnoses PCOS. The Rotterdam consensus accepted two of three features (oligo-ovulation or anovulation, hyperandrogenism, and polycystic ovarian morphology) once other causes are excluded (1). Earlier criteria placed more weight on androgen excess (12), and the international guideline retained the Rotterdam approach (3). Prevalence depends on the criteria applied (13, 14).

For thyroid studies the heterogeneity matters: a sample of women with the full anovulatory, hyperandrogenic phenotype is more insulin-resistant than one including milder phenotypes (15, 16). PCOS probably arises from genetic susceptibility, androgen production and metabolic factors (17, 18), and guidance advises excluding thyroid disease in the work-up because it

can mimic some features (19). This is why the same condition can look common in one report and unremarkable in the next.

2.2 Thyroid Function and How Abnormality Is Defined

Thyroid hormones act on nearly every tissue by altering gene expression (20), and they regulate energy expenditure, lipid handling and glucose metabolism (21). Thyroid status is judged mainly from serum thyrotropin, which rises when the gland under-performs, with free thyroxine and, where autoimmunity is suspected, antibodies to thyroid peroxidase (22). Table 1 lists the states discussed.

Defining abnormal is less simple than it sounds. Some authors contend that the upper thyrotropin limit is set too high because people with occult thyroid disease were included when it was derived (30, 31). Subclinical hypothyroidism, a raised thyrotropin with normal free thyroxine, is the state most often reported in PCOS, and its clinical significance remains debated (25, 32). Small shifts in a laboratory cut-off can move many women across the line without any change in their physiology.

Table 1. Thyroid states discussed in this review.

State	Pattern	Comment
Overt hypothyroidism	TSH high, free T4 low	Treated (23, 24)
Subclinical hypothyroidism	TSH high, free T4 normal	Debated (25, 26)
Thyroid autoimmunity	Antibodies present	Female excess (27, 28)
Hashimoto thyroiditis	Autoimmune gland damage	Usual cause (29)

Note: Qualitative; reference ranges differ between laboratories, so no cut-offs are given.

2.3 Thyroid Autoimmunity in Women

Autoimmune thyroid disease is considerably more common in women than in men (27), part of a wider female excess



of autoimmune disease (28). Hashimoto thyroiditis is the usual cause of hypothyroidism in iodine-sufficient regions (29), and antibodies are found in a sizeable minority of symptom-free women (5, 33), so they would turn up in some women with PCOS even if the conditions were unrelated.

Even so, several groups report antibodies or ultrasound features of thyroiditis more often in women with PCOS than in controls (7, 8). One group suggested that the oestradiol–progesterone balance, disturbed in anovulatory women, might favour autoimmunity (34). The idea rests on association alone. Read this way, a normal result in a small sample is not proof that the abnormality is absent.

2.4 Insulin Resistance, Adiposity and Lipids

Insulin resistance is a central feature of many cases of PCOS, amplified by body weight (15), and women with PCOS have higher rates of impaired glucose tolerance and diabetes (16). Thyroid hormone and insulin act on overlapping pathways (35), so a metabolic route from PCOS to a raised thyrotropin is plausible.

Body weight is the most obvious confounder. Thyrotropin tends to rise with body mass index in population studies (36, 37), and many women with PCOS carry excess weight. Yet one study found thyrotropin associated with insulin resistance in PCOS independently of body mass index (38), so weight alone may not explain everything. Thyroid dysfunction also alters lipids (39), adding to the cardiometabolic picture of PCOS, a picture already shaped by weight, glucose handling and androgen excess. A raised thyrotropin here has more than one possible cause. The point is not that these

studies are poor, only that their results travel less far than the abstracts suggest.

3. Materials and Methods

3.1 Scope and Question

The review asks one question in three parts. Are thyroid abnormalities, chiefly subclinical hypothyroidism and autoimmunity, reported more often in women with PCOS? What mechanisms explain any excess? And how reliable are the reports? The question was divided into points on which a study can succeed or fail, such as definitions, sampling and confounding. None of these steps is complicated, but each is easy to skip when a result looks familiar.

3.2 Literature Assembly

The review draws on published, peer-reviewed work on PCOS diagnosis and phenotypes, thyroid physiology and measurement, thyroid autoimmunity, insulin resistance and adiposity, and reproductive outcomes. Sources were chosen for relevance, standing in the field and clarity of method; guidelines and large reviews framed definitions.

No formal systematic search was run and none is claimed. This is a narrative synthesis, and the selection of sources reflects the authors' judgement. The review is thus a guide to the structure of the evidence, not to the size of any association, and it quotes no prevalence figures from individual studies.

3.3 Appraisal Framework

Each study was read against five questions, summarised in Table 2: which PCOS criteria were used, which thyrotropin limit defined abnormality, whether weight was reported, whether antibodies were measured, and who was sampled. Each is



quick to check and easy to overlook. It is a habit worth keeping even when the answer seems obvious.

Table 2. Questions used to appraise studies of thyroid function in PCOS.

Question	Why it matters	Sources
Which PCOS criteria?	Phenotypes differ	(1, 13)
Which TSH limit?	Cut-offs change case counts	(30, 31)
Weight reported?	Adiposity raises TSH	(36, 37)
Antibodies measured?	Separates autoimmune cases	(22)

Note: The authors' working framework, not a validated instrument.

4. Results

4.1 What the Studies Describe

The most consistent finding across the clinical series is a higher frequency of subclinical hypothyroidism, or raised thyrotropin, in women with PCOS (9, 38). Overt hypothyroidism is described less often, and overt hyperthyroidism hardly at all: the shift is at the mild end of the distribution (26). Figure 1 sketches the layers through which the thyroid and ovarian systems might interact.

Many of these reports are cross-sectional, single-centre and based on women attending a specialist clinic. Referral selects for women whose symptoms are more severe or whose results are already abnormal, and a clinic sample is rarely a random one, so the numbers do not describe PCOS in the community (6, 33).




Figure 1. Layers through which thyroid and ovarian axes may interact (schematic, not data).

4.2 Autoimmunity and the Hormonal Milieu

Reports of thyroid autoimmunity are more striking than those of dysfunction. Several authors found antibodies or sonographic signs of thyroiditis more often in women with PCOS (7, 8, 34). If real, this supports a shared autoimmune or hormonal background (Table 3). If not, it may reflect selection, since a woman already under endocrine review is more likely to have her antibodies checked. Many antibody-positive women keep a normal thyrotropin for years (27, 29).

Table 3. Proposed links between thyroid function and PCOS.

Link	Basis	Status
Shared autoimmunity	Clustering in some series (7, 8)	Mixed
Insulin resistance	Thyroid hormone alters glucose handling (21, 35)	Plausible
Adiposity	Weight and TSH rise together (36, 37)	Likely
Sex hormones	Oestrogen–progesterone balance (28, 34)	Speculative

Note: Status is the authors' reading of the cited work, not a formal grading.

4.3 Measurement, Confounding and Reading a Raised Result

Reference limits differ between laboratories and populations, and a woman



can be classed as normal in one and abnormal in another (22, 30). Figure 2 maps how consistent the literature is on each question. Thyrotropin also varies within a person from day to day, so a single raised value may not persist on repeat testing. A thyroid result taken once, on one morning, is a snapshot and not a diagnosis.

Weight and insulin resistance can raise thyrotropin on their own (35, 36, 37), so a mildly raised value does not necessarily mean thyroid disease. A reasonable reading sequence (Figure 3) is to repeat the test, check free thyroxine and antibodies, consider weight and recent illness, and only then decide what the value reflects (23, 24). This describes how reports are best read, not advice for an individual patient.

Mild elevations of thyrotropin in non-pregnant adults often settle on their own, and the benefit of treating them is uncertain (25, 26); in women planning pregnancy guidelines recommend closer attention (40). Timing matters as well, because a value measured during illness or rapid weight change may read differently later. Irregular cycles complicate this further, since no single day means the same thing in every woman.




Figure 2. Qualitative evidence map by question; shading shows how consistent the literature is, not any count (schematic, not data).

4.4 Treatment and Its Effects on Thyroid Tests

Metformin is widely used in PCOS to improve insulin sensitivity, and a study of women with PCOS reported a fall in thyrotropin during treatment (41). If that holds, some of the apparent thyroid abnormality may be reversible through the metabolic route, though the evidence is limited to small studies and the mechanism is not established. Replacement therapy for overt hypothyroidism is well established (23, 24); for mild elevations the decision to treat is individual and guideline-dependent (19, 32).

In short, the literature supports only a cautious statement. Raised thyrotropin and thyroid antibodies appear to be reported more often in women with PCOS, the mild end of thyroid dysfunction is the most affected, and obesity, insulin resistance and autoimmunity are all candidate explanations. How much of the excess is real, and how much reflects selection, measurement and weight, is not settled. That is a modest conclusion, and it is the one the literature currently supports.




Figure 3. Reading a raised thyrotropin result in a woman with PCOS (schematic decision sequence, not data).

5. Discussion



5.1 Interpretation

The main finding is a conditional one. Thyroid abnormalities are reported more often in women with PCOS in many, but not all, studies, concentrated in subclinical hypothyroidism and autoimmunity. That fits both a shared autoimmune background and a metabolic explanation through insulin resistance and adiposity (17, 21), and the present literature cannot choose between them. Nothing in this reading argues against testing; it argues for interpreting each result in context.

5.2 Limitations

This is a narrative review and shares the limitations of that form. Source selection reflects judgement, no formal search or quality scoring was done, and no prevalence figures are quoted. Several of the clinical series cited are small and single-centre, and are cited for the pattern they describe, not for effect sizes. Reviews are more useful when they say where the evidence stops than when they smooth it over.

5.3 Directions for Future Work

Three needs stand out: prospective studies that recruit women with PCOS by one stated set of criteria and compare them with weight-matched women using the same laboratory and thyrotropin limit; follow-up of antibody-positive women; and trials of whether treating mild thyroid abnormalities changes ovulation, pregnancy or metabolic outcomes. These points apply with equal force to many other conditions that cluster with PCOS, not to the thyroid alone.

6. Conclusion

Thyroid function abnormalities, chiefly subclinical hypothyroidism and thyroid autoimmunity, are reported more often in women with PCOS than in comparison groups, though not uniformly. The reports

are limited by differing criteria, reference limits, body weight, referral patterns and small samples, and autoimmune and metabolic explanations are both plausible but unproven. Thyroid assessment is a reasonable part of the evaluation of PCOS, and a raised thyrotropin should be read with attention to weight, antibodies and repeat testing.

7. Acknowledgements

The authors thank colleagues who commented on earlier drafts of this review.

8. Funding

This work received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

9. Conflict of Interest

The authors declare no conflict of interest.

10. Author Contributions

C.K. conceived the review and wrote the sections on PCOS and reproductive outcomes. N.A. wrote the sections on thyroid physiology and autoimmunity. O.P. wrote the sections on metabolic factors and the appraisal of studies. All authors revised the manuscript and approved the final version.

11. Ethics Statement

This is a review of published literature. No human participants or animals were involved and no ethical approval was required.

12. Data Availability

No new data were generated. All sources are cited in the reference list.

13. References

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary



- syndrome (PCOS). *Human Reproduction*, 19(1), 41–47. DOI: [10.1093/humrep/deh098](https://doi.org/10.1093/humrep/deh098)
2. Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., ... Yildiz, B. O. (2016). Polycystic ovary syndrome. *Nature Reviews Disease Primers*, 2, 16057. DOI: [10.1038/nrdp.2016.57](https://doi.org/10.1038/nrdp.2016.57)
 3. Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., ... Norman, R. J. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Human Reproduction*, 33(9), 1602–1618. DOI: [10.1093/humrep/dey256](https://doi.org/10.1093/humrep/dey256)
 4. Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2015). Complications and challenges associated with polycystic ovary syndrome: Current perspectives. *International Journal of Women's Health*, 7, 745–763. DOI: [10.2147/IJWH.S70314](https://doi.org/10.2147/IJWH.S70314)
 5. Hollowell, J. G., Staehling, N. W., Flanders, W. D., ... Braverman, L. E. (2002). Serum TSH, T₄, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *Journal of Clinical Endocrinology & Metabolism*, 87(2), 489–499. DOI: [10.1210/jcem.87.2.8182](https://doi.org/10.1210/jcem.87.2.8182)
 6. Vanderpump, M. P. J., Tunbridge, W. M. G., French, J. M., Appleton, D., Bates, D., Clark, F., ... Young, E. T. (1995). The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. *Clinical Endocrinology*, 43(1), 55–68. DOI: [10.1111/j.1365-2265.1995.tb01894.x](https://doi.org/10.1111/j.1365-2265.1995.tb01894.x)
 7. Janssen, O. E., Mehlmauer, N., Hahn, S., Öffner, A. H., & Gärtner, R. (2004). High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. *European Journal of Endocrinology*, 150(3), 363–369. DOI: [10.1530/eje.0.1500363](https://doi.org/10.1530/eje.0.1500363)
 8. Garelli, S., Masiero, S., Plebani, M., ... Betterle, C. (2013). High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 169(2), 248–251. DOI: [10.1016/j.ejogrb.2013.03.003](https://doi.org/10.1016/j.ejogrb.2013.03.003)
 9. Sinha, U., Sinharay, K., Saha, S., ... Pal, S. K. (2013). Thyroid disorders in polycystic ovarian syndrome subjects: A tertiary hospital based cross-sectional study from Eastern India. *Indian Journal of Endocrinology and Metabolism*, 17(2), 304–309. DOI: [10.4103/2230-8210.109714](https://doi.org/10.4103/2230-8210.109714)
 10. Krassas, G. E., Poppe, K., & Glinioer, D. (2010). Thyroid function and human reproductive health. *Endocrine Reviews*, 31(5), 702–755. DOI: [10.1210/er.2009-0041](https://doi.org/10.1210/er.2009-0041)
 11. Poppe, K., Velkeniers, B., & Glinioer, D. (2007). Thyroid disease and female reproduction. *Clinical Endocrinology*, 66(3), 309–321. DOI: [10.1111/j.1365-2265.2007.02752.x](https://doi.org/10.1111/j.1365-2265.2007.02752.x)
 12. Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., ... Witchel, S. F. (2009). The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. *Fertility and Sterility*, 91(2), 456–488. DOI: [10.1016/j.fertnstert.2008.06.035](https://doi.org/10.1016/j.fertnstert.2008.06.035)
 13. Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavriloja-Jordan, L., & Azziz, R. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. *Fertility and Sterility*, 106(1), 6–15. DOI: [10.1016/j.fertnstert.2016.05.003](https://doi.org/10.1016/j.fertnstert.2016.05.003)
 14. Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016). The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis. *Human Reproduction*, 31(12), 2841–2855. DOI: [10.1093/humrep/dew218](https://doi.org/10.1093/humrep/dew218)
 15. Dunaif, A. (1997). Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. *Endocrine Reviews*, 18(6), 774–800. DOI: [10.1210/edrv.18.6.0318](https://doi.org/10.1210/edrv.18.6.0318)
 16. Moran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010). Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. *Human Reproduction Update*, 16(4), 347–363. DOI: [10.1093/humupd/dmq001](https://doi.org/10.1093/humupd/dmq001)
 17. Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. *Nature Reviews Endocrinology*, 7(4), 219–231. DOI: [10.1038/nrendo.2010.217](https://doi.org/10.1038/nrendo.2010.217)
 18. Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. *Nature Reviews Endocrinology*, 14(5), 270–284. DOI: [10.1038/nrendo.2018.24](https://doi.org/10.1038/nrendo.2018.24)
 19. Legro, R. S., Arslanian, S. A., Ehrmann, D. A., ... Welt, C. K. (2013). Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology & Metabolism*, 98(12), 4565–4592. DOI: [10.1210/jc.2013-2350](https://doi.org/10.1210/jc.2013-2350)
 20. Brent, G. A. (2012). Mechanisms of thyroid hormone action. *Journal of Clinical Investigation*, 122(9), 3035–3043. DOI: [10.1172/JCI60047](https://doi.org/10.1172/JCI60047)
 21. Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014). Thyroid hormone regulation of metabolism. *Physiological Reviews*, 94(2), 355–382. DOI: [10.1152/physrev.00030.2013](https://doi.org/10.1152/physrev.00030.2013)



22. Baloch, Z., Carayon, P., Conte-Devolx, B., Demers, L. M., Feldt-Rasmussen, U., Henry, J.-F., ... Stockigt, J. (2003). Laboratory medicine practice guidelines: Laboratory support for the diagnosis and monitoring of thyroid disease. *Thyroid*, 13(1), 3–126. DOI: [10.1089/105072503321086962](https://doi.org/10.1089/105072503321086962)
23. Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., ... Woeber, K. A. (2012). Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Thyroid*, 22(12), 1200–1235. DOI: [10.1089/thy.2012.0205](https://doi.org/10.1089/thy.2012.0205)
24. Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017). Hypothyroidism. *The Lancet*, 390(10101), 1550–1562. DOI: [10.1016/S0140-6736\(17\)30703-1](https://doi.org/10.1016/S0140-6736(17)30703-1)
25. Surks, M. I., Ortiz, E., Daniels, G. H., Sawin, C. T., Col, N. F., Cobin, R. H., ... Weissman, N. J. (2004). Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. *JAMA*, 291(2), 228–238. DOI: [10.1001/jama.291.2.228](https://doi.org/10.1001/jama.291.2.228)
26. Cooper, D. S., & Biondi, B. (2012). Subclinical thyroid disease. *The Lancet*, 379(9821), 1142–1154. DOI: [10.1016/S0140-6736\(11\)60276-6](https://doi.org/10.1016/S0140-6736(11)60276-6)
27. McLeod, D. S. A., & Cooper, D. S. (2012). The incidence and prevalence of thyroid autoimmunity. *Endocrine*, 42(2), 252–265. DOI: [10.1007/s12020-012-9703-2](https://doi.org/10.1007/s12020-012-9703-2)
28. Whitacre, C. C. (2001). Sex differences in autoimmune disease. *Nature Immunology*, 2(9), 777–780. DOI: [10.1038/ni0901-777](https://doi.org/10.1038/ni0901-777)
29. Caturegli, P., De Remigis, A., & Rose, N. R. (2014). Hashimoto thyroiditis: Clinical and diagnostic criteria. *Autoimmunity Reviews*, 13(4–5), 391–397. DOI: [10.1016/j.autrev.2014.01.007](https://doi.org/10.1016/j.autrev.2014.01.007)
30. Wartofsky, L., & Dickey, R. A. (2005). The evidence for a narrower thyrotropin reference range is compelling. *Journal of Clinical Endocrinology & Metabolism*, 90(9), 5483–5488. DOI: [10.1210/jc.2005-0455](https://doi.org/10.1210/jc.2005-0455)
31. Spencer, C. A., Hollowell, J. G., Kazarosyan, M., & Braverman, L. E. (2007). National Health and Nutrition Examination Survey III thyroid-stimulating hormone (TSH)–thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. *Journal of Clinical Endocrinology & Metabolism*, 92(11), 4236–4240. DOI: [10.1210/jc.2007-0287](https://doi.org/10.1210/jc.2007-0287)
32. Fatourechi, V. (2009). Subclinical hypothyroidism: An update for primary care physicians. *Mayo Clinic Proceedings*, 84(1), 65–71. DOI: [10.4065/84.1.65](https://doi.org/10.4065/84.1.65)
33. Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000). The Colorado thyroid disease prevalence study. *Archives of Internal Medicine*, 160(4), 526–534. DOI: [10.1001/archinte.160.4.526](https://doi.org/10.1001/archinte.160.4.526)
34. Arduc, A., Aycicek Dogan, B., Bilmez, S., Imga Nasiroglu, N., Tuna, M. M., Isik, S., ... Guler, S. (2015). High prevalence of Hashimoto's thyroiditis in patients with polycystic ovary syndrome: Does the imbalance between estradiol and progesterone play a role? *Endocrine Research*, 40(4), 204–210. DOI: [10.3109/07435800.2015.1015730](https://doi.org/10.3109/07435800.2015.1015730)
35. Brenta, G. (2011). Why can insulin resistance be a natural consequence of thyroid dysfunction? *Journal of Thyroid Research*, 2011, 152850. DOI: [10.4061/2011/152850](https://doi.org/10.4061/2011/152850)
36. Fox, C. S., Pencina, M. J., D'Agostino, R. B., ... Vasan, R. S. (2008). Relations of thyroid function to body weight: Cross-sectional and longitudinal observations in a community-based sample. *Archives of Internal Medicine*, 168(6), 587–592. DOI: [10.1001/archinte.168.6.587](https://doi.org/10.1001/archinte.168.6.587)
37. Knudsen, N., Laurberg, P., Rasmussen, L. B., ... Jørgensen, T. (2005). Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. *Journal of Clinical Endocrinology & Metabolism*, 90(7), 4019–4024. DOI: [10.1210/jc.2004-2225](https://doi.org/10.1210/jc.2004-2225)
38. Mueller, A., Schöfl, C., Dittrich, R., Cupisti, S., Oppelt, P. G., Schild, R. L., ... Häberle, L. (2009). Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. *Human Reproduction*, 24(11), 2924–2930. DOI: [10.1093/humrep/dep285](https://doi.org/10.1093/humrep/dep285)
39. Duntas, L. H. (2002). Thyroid disease and lipids. *Thyroid*, 12(4), 287–293. DOI: [10.1089/10507250252949405](https://doi.org/10.1089/10507250252949405)
40. Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., ... Sullivan, S. (2017). 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid*, 27(3), 315–389. DOI: [10.1089/thy.2016.0457](https://doi.org/10.1089/thy.2016.0457)
41. Rotondi, M., Cappelli, C., Magri, F., Botta, R., Dionisio, R., Iacobello, C., ... Chiovato, L. (2011). Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. *Clinical Endocrinology*, 75(3), 378–381. DOI: [10.1111/j.1365-2265.2011.04056.x](https://doi.org/10.1111/j.1365-2265.2011.04056.x)